ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Open access · bronzeAbstract readValidation Study
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Head-to-head comparison of [Pediatric radiology · 2026Pooled it
- The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.Journal of hematology & oncology · 2025Trial
- The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.Nature communications · 2025Trial
- Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.Pediatric blood & cancer · 2023Trial
- Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.European journal of nuclear medicine and molecular imaging · 2018Trial
- [JMIR research protocols · 2026Article
- Prognostic Value of a Semi-Quantitative Score Based on 123 I-MIBG SPECT/CT in Pediatric Patients With Stage 4 High-Risk Neuroblastoma After Induction Therapy.Clinical nuclear medicine · 2026Article
- International neuroblastoma risk group consortium: a model of networking for rare cancers.Journal of the National Cancer Institute · 2026Article
- Article
- Established and Emerging Therapies for High-Risk Neuroblastoma.Paediatric drugs · 2026Review
- Discrepancies between primary and secondary interpretations of pediatric nuclear medicine imaging examinations.Pediatric radiology · 2026Article
- Fractal Dimension of High-Risk Neuroblastoma Vascularity in MRI Is Associated with Chemotherapy Response and Event-Free Survival.Radiology. Imaging cancer · 2026Article
- White paper on the current state of imaging biomarkers in paediatric oncology.Pediatric radiology · 2025Review
- Histologic Response to Induction Chemotherapy in High-Risk Neuroblastoma.Cancer medicine · 2025Article
- Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Application of modified Curie and SIOPEN skeleton scoring systems inAnnals of nuclear medicine · 2025Article
- Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 17 institutions in 9 countries.
Gregory A YanikDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical Center, Ann Arbor, Michigan gyanik@umich.edu.
Marguerite T ParisiDepartment of Radiology, University of Washington School of Medicine/Seattle Children's Hospital, Seattle, Washington.
Arlene NaranjoChildren's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida.
Helen NadelDepartment of Radiology, BC Children's Hospital, Vancouver, British Columbia, Canada.
Michael J GelfandDepartment of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Julie R ParkDepartment of Pediatrics, University of Washington School of Medicine/Seattle Children's Hospital, Seattle, Washington.
Ruth L LadensteinDepartment of Pediatrics, St. Anna Children's Hospital, Vienna, Austria.
Ulrike PoetschgerDepartment of Statistics, St. Anna Children's Cancer Research Institute, Vienna, Austria.
Ariane BoubakerInstitute of Radiology, Clinique de La Source, Lausanne, Switzerland.
Dominique Valteau-CouanetDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Institute, Universite Paris-Sud, Villejuif, France.
Bieke LambertRadiology and Nuclear Medicine, Ghent University, Ghent, Belgium.
Maria-Rita CastellaniNuclear Medicine Division, Istituto Nazionale Tumori di Milano, Milan, Italy.
Zvi Bar-SeverSchneider Children's Medical Center of Israel, Petah-Tivka, Israel.
Aurore OudouxCentre Oscar-Lambret, Lille, France.
Anna KaminskaChildren's Memorial Health Institute, Warsaw, Poland.
Susan G KreissmanDepartment of Pediatrics, Duke University Medical Center, Durham, North Carolina.
Barry L ShulkinDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee; and.
Katherine K MatthayDepartment of Pediatrics, University of California San Francisco School of Medicine, San Francisco, California.
University of Washington · USBritish Columbia Children's Hospital · CACentre Oscar Lambret · FRChildren's Memorial Health Institute · PLCincinnati Children's Hospital Medical Center · USClinique de La Source · CHDuke Medical Center · USFondazione IRCCS Istituto Nazionale dei Tumori · ITGhent University Hospital · BESchneider Children's Medical Center · ILSt. Anna Children's Cancer Research InstituteSt Anna Children's Hospital · ATSt. Jude Children's Research Hospital · USUniversité Paris-Sud · FRUniversity of California, San Francisco · USUniversity of Florida · USUniversity of Michigan–Ann Arbor · US
Funding
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MNCI NIH HHS U10 CA180899
Abstract
A semiquantitative
Indexed as
Research ReportSocieties, Medical3-IodobenzylguanidineAdolescentChildChild, PreschoolFemaleHumansInfantMaleNeuroblastomaPrognosisRisk3-IodobenzylguanidineCurie scoreMIBGneuroblastoma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.